We have recently identified the insulin-like peptide relaxin-3 (aka INSL7) as the endogenous ligand for an orphan G-protein coupled receptor, GPCR135 (aka SALPR).
Introduction
Relaxin-3 (1) is a member of the insulin superfamily, where each member consists of two peptide subunits arranged by three disulfide bridges. Recently, two leucine-rich repeatcontaining G-protein coupled receptors (LGRs), LGR7 and LGR8 (2, 3) , have been identified as the receptors for relaxin (3) (4) (5) (6) (7) .
LGR7 and LGR8 belong to the type III hormone receptor family (FSH, LH, TRH etc which stimulate adenylate cyclase).
Relaxin-3 was recently demonstrated to be an additional ligand for the relaxin receptor
LGR7, but not LGR8 (8). Instead, the ligand INSL3 (9), another member of the insulin/relaxin family of peptides, has been shown to be an additional ligand for LGR8 (10).
As part of directed effort to identify ligands for orphan G-protein coupled receptors (GPCRs), we established a systematic program to create tissue extracts as a source of possible GPCR ligands. In a concurrent publication, we report the purification and identification of the peptide ligand, relaxin-3, as an endogenous ligand for orphan receptor GPCR135, aka SALPR. In that report, we first demonstrated that an insulin-like peptide binds to and activates a type I GPCR with high affinity with a K d value of approximately 300 pM. We have tested all known insulin/relaxin peptides, including
Molecular Cloning of GPCR142
Human GPCR142 sequence was identified from the human genome (Genbank Accession No.: AL355388) based on its homology to GPCR135. The complete coding region of human GPCR142 was PCR amplified from human genomic DNA using two primers 
Expression, purification, and iodination of human relaxin-3
Human recombinant relaxin-3 was expressed in mammalian cells and purified as described in our concurrent report (Liu et. al.) . The purified relaxin-3 was labeled using 
GTPγS binding assays
The GPCR142 expression vector described above was transfected into CHO cells using Lipofectamine (Invitrogen, San Diego, CA) according to the manufacturer's instructions.
Two days after transfection, the cells were harvested and the cell membranes were prepared by homogenizing the cells in cold 50 mM Tris-HCl, 5 mM EDTA, pH 7.5 followed by centrifugation at 4 o C 1000 g for 10 min. The supernatant was centrifuged at 4 o C 20, 000 g for 30 min and the pellet was re-suspended in GTPγS binding buffer: 50
mM Tris-HCl, pH 7.4, 10 mM MgCl 2 , 1 mM EDTA pH 8.0, and 100 mM NaCl using a polytron tissue homogenizer. Protease inhibitors were added to the buffer at 
Ca

2+ mobilization assays
Human embryonic kidney (HEK) 293 cells were transfected with GPCR135, GPCR142
or co-transfected with Gq i5 (13) or G α16 (14) expressing plasmids using LipofectAmine. 
Results
Identification and sequence analysis of GPCR142
GPCR135, which we recently identified as a receptor for relaxin-3, was used as a query sequence to search the human genome using the NCBI Blast search program. We found that there exists a putative orphan GPCR, designated as GPCR142, which shares the highest overall sequence identity (43%) to GPCR135 among all GPCRs. Within the transmembrane domain regions the two receptors share greater than 50% amino acid sequence identity ( Fig.1) . We have cloned the complete coding region of human GPCR142 from the human genomic DNA using PCR amplification. 
Functional characterization of GPCR142 by GTPγS binding and cAMP accumulation inhibition assays
In a concurrent publication (Liu et. al.) , we have shown that relaxin-3 stimulated GTPγS binding and inhibits cAMP accumulation in GPCR135 over-expressing cells. We activity with an EC 50 value of 88 ± 18 nM (Fig. 4) . In a parallel experiment, the same cells were assayed for β-gal expression, which represents the intracellular cAMP 
Characterization of GPCR142 by Ca 2+ mobilization assays
Gq i5 has been reported to be able to shift the signal transduction of GPCRs from cAMP inhibition to calcium mobilization (12) . In a concurrent report ( 
GPCR142 mRNA tissue expression profile
Using RT-PCR, we studied GPCR142 mRNA expression in different human tissues. Our results showed that GPCR142 mRNA expression pattern is very different from that of GPCR135. In our concurrent publication (Liu et. al.) , we have shown that GPCR135 mRNA is only found in brain, testis, thymus and adrenal gland. GPCR142 mRNA is found in a broader range of tissues including brain, kidney, testis, thymus, placenta, prostate, salivary gland, thyroid, and colon. (Fig. 6) .
Discussion
Relaxin-3, a member of insulin super-family, has been shown to be a ligand for LGR7. In our concurrent publication, we have shown that relaxin-3 is also a ligand for GPCR135
(aka SALPR). In fact it can be argued that relaxin-3 is the true ligand for GPCR135 since
LGR7 expression is more consistent with its role as a relaxin receptor. The significant homology of GPCR142 and GPCR135 led us to hypothesize that GPCR142 may also be a receptor for relaxin-3. We characterized GPCR142 by radioligand binding, GTPγS binding, cAMP accumulation, and Ca 2+ mobilization assays. Our results indicate that relaxin-3 is a high affinity ligand for GPCR142 and we conclude that GPCR142 is an additional receptor for relaxin-3.
Pharmacologically, GPCR142 behaves similarly to GPCR135 in the majority of assays In our concurrent publication, we have showed that Gq i5 is capable of shifting the signal transduction of GPCR135 into Ca 2+ mobilization. One significant difference between GPCR142 and GPCR135 is that relaxin-3 does not stimulate any detectable Ca 2+ signal in HEK293 cells co-expressing GPCR142 and Gq i5 (data not shown). One reason could be that Gq i5 , an artificial chimeric G-protein, does not couple to all G i -linked GPCRs. We have observed a similar phenomenon when we studied GPR7 and GPR8 (18, 19), two highly related neuro-peptide W (NPW) receptors linked to cAMP inhibition. While NPW stimulated Ca 2+ mobilization in HEK293 cells co-expressing GPR7 and Gq i5, it did not do the same for cells co-expressing GPR8 and Gq i5 (unpublished). Gα 16 seems to be capable of coupling with both GPCR142 and GPCR135 and shifting their signal transduction into Ca 2+ signaling. However, relaxin-3 showed significantly lower potency in Ca 2+ assays compared with those derived from other assays for both GPCR142 and GPCR135. We have observed a similar phenomenon for a few other Gi-linked receptors (20, 21) and we hypothesize that the difference could be due to either the non-natural receptor/G-protein coupling or due to the pre-equilibrium nature of the Ca 2+ mobilization assays.
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Another marked difference between GPCR142 and GPCR135 is their mRNA expression patterns. While GPCR135 mRNA is expressed in restricted tissues with the predominant expression in the brain (22), GPCR142 mRNA is expressed in a broader range of peripheral tissues, suggesting that GPCR142 may have a different physiological role from that of GPCR135. Since relaxin-3 is primarily expressed in the brain, the relative abundant expression of GPCR142 in the peripheral tissues also suggests the possible existence of an additional ligand (other than relaxin-3) expressed in peripheral tissues.
Future studies to look for additional insulin/relaxin related peptide will help find whether there is another ligand for GPCR142. In addition, knowing that GPCR142 belongs to the type I GPCR family similar to somatostatin and angiotensin receptors, it is also possible that GPCR142 is activated by a different ligand, for example a peptide that is not in the insulin/relaxin family.
We have searched the rat and mouse genome with human GPCR135 and GPCR142 sequences as the queries. 
Figure Legends
Figure1. Amino acid sequence comparison between human GPCR142 and GPCR135.
The putative transmembrane domains, designated TM1 to TM7, are underlined. 
